---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222762"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2026-05-14T11:12:20+00:00"
generated_at: "2026-05-14T11:15:09.625730+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q1 net product revenue $13.7M (+22% YoY); net loss $41.4M; VYD2311 data delayed to Q3 2026

## Summary
- Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY vs $11.3M.
- Net loss $41.4M ($0.13/sh) vs $16.3M ($0.14/sh) in Q1 2025; R&D expense rose to $30.7M.
- Cash $184.2M at Mar 31; raised ~$20M via ATM in Apr 2026, extending runway through VYD2311 launch.
- DECLARATION trial upsized by ~500 subjects; top-line data now expected in Q3 2026 (shift from mid-year).
- IDMC reduced VYD2311 post-dose monitoring from 2 hours to 30 min; in vitro neutralization vs BA.3.2.2 confirmed.

## SEC filing metadata
- accession: 0001193125-26-222762
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2026-05-14T11:12:20+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/0001193125-26-222762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222762
- JSON: https://secwatch.observer/filing/0001193125-26-222762.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.